<DOC>
	<DOCNO>NCT00952380</DOCNO>
	<brief_summary>Three month treatment acute VTE Fragmin pediatric cancer patient</brief_summary>
	<brief_title>Fragmin Treatment Acute VTE Pediatric Cancer Patients</brief_title>
	<detailed_description>Primary study objective include determine pharmacodynamic ( PD ) profile treatment dos dalteparin pediatric subject different age cancer venous thromboembolism ( VTE ) , use anti-Xa ( Xa ) level population PD analysis methodology , determine median dose require achieve therapeutic anti- Xa level ( 0.5 1.0 International Units [ IU ] /mL ) base subject age weight .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>VTE</keyword>
</DOC>